SPOTLIGHT: FDA hold lifted on Cortex drug

The FDA has lifted a clinical hold put on a study of Cortex's Ampakine CX717 for Alzheimer's. Cortex agreed to the FDA's dose range and has been gathering new toxicology data. Cortex stock jumped 18 percent on the news. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.